| Thiopurine Enhanced Mutations for PD-1/Ligand-1 Efficacy (NCT05276284) | Kristoffer Rohrberg | 2022-09-01 |
| Phase Ⅱ Study of Chidamide in Combination With CHOP in Previously Untreated Peripheral T-Cell Lymphoma With Follicular Helper of T Cell Phenotype (NCT05572983) | Sun Yat-sen University | 2022-09-01 |
| Lenvatinib Plus Tislelizumab With or Without TACE in First-line Treatment of Unresectable HCC (NCT05842317) | Peking Union Medical College Hospital | 2022-09-01 |
| Isatuximab and Bendamustine in Systemic Light Chain Amyloidosis (NCT04943302) | Tufts Medical Center | 2022-09-01 |
| TNFα Monoclonal Antibody for Acute Spinal Cord Injury (NCT04988425) | Shanghai Changzheng Hospital | 2022-09-01 |
| Treating Chronic Cervicogenic Head and Neck Pain (NCT05617365) | Michigan State University | 2022-09-01 |
| LiST Plus PRP Injection Therapy vs LiST Monotherapy for ED Treatment (NCT05366504) | Institute for the Study of Urological Diseases, Greece | 2022-09-01 |
| Multi-omics Sequencing in Neoadjuvant Immunotherapy of Gastrointestinal Tumors (NCT05515796) | Daping Hospital and the Research Institute of Surgery of the Third Military Medical University | 2022-09-01 |
| Efficacy and Safety of OPL-0301 Compared to Placebo in Adults With Post-Myocardial Infarction (MI) (NCT05327855) | Valo Health, Inc. | 2022-09-01 |
| Anticoagulation-free VV ECMO for Acute Respiratory Failure (NCT04273607) | Damian Ratano | 2022-09-01 |
| A Trial of LY3056480 in Patients With SNLH (NCT05061758) | Audion Therapeutics BV | 2022-09-01 |
| PRaG Regimens Rechallenge for Patients With Resistance to PD1/PD-L1 Inhibitors in Refractory Advanced Solid Tumors. (NCT05530200) | Second Affiliated Hospital of Soochow University | 2022-09-01 |
| A Clinical Study of 6MW3211 in Patients With Renal Cancer (NCT05440045) | Mabwell (Shanghai) Bioscience Co., Ltd. | 2022-09-01 |
| Neoadjuvant Encorafenib, Binimetinib and Cetuximab for Patients With BRAF V600E Mutated/pMMR Localized Colorectal Cancer (NCT05510895) | AIO-Studien-gGmbH | 2022-09-01 |
| Neoadjuvant Therapy for Locally Advanced Rectal Cancer With Fruquintinib, Toripalimab and SRT (NCT05763927) | West China Hospital | 2022-09-01 |
| A 6 Months Double Blind Trial to Prevent PONV in Laparoscopic Cholecystectomy (NCT05529004) | Al Safwa University College | 2022-09-01 |
| Hydrogen Peroxide Trial to Investigate the Efficacy of 30%H2O2 as a Topical Application Before Definitive Treatment (NCT04929535) | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | 2022-09-01 |
| HAIC Combined With Donafenib Tosilate and Toripalimab for Unresectable HCC (NCT05493332) | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 2022-09-01 |
| Study to Evaluate Sutetinib Maleate Capsule in Locally Advanced or Metastatic Non-small Cell Lung Cancer (NCT05168566) | Teligene US | 2022-09-01 |
| A Study of XZP-3621 in Chinese Patients With ALK Positive NSCLC (NCT05482087) | Xuanzhu Biopharmaceutical Co., Ltd. | 2022-09-01 |
| Phase II Study of Niraparib in Metastatic TNBC Patients With Homologous Recombination Deficiency (NCT05461690) | Zhejiang Cancer Hospital | 2022-09-01 |
| Pembrolizumab in Combination With Low-dose PFas Neoadjuvant Treatment for Locally Advanced HNSCC (NCT05446467) | Zhejiang Provincial People's Hospital | 2022-09-01 |
| Clinical Study of Camrelizumab, Apatinib Mesylate and Nab-paclitaxel Combined With Oxplatin and S-1 in the Neoadjuvant Treatment of Locally Advanced Gastric Cancer With Different Genotypes (NCT05524974) | Fujian Medical University | 2022-09-01 |
| Phase 2 Multi-center Randomized Study to the Efficacy and Safety of AK105 Combined With Anrotinib Hydrochloride in Patients With Recurrent/Refractory Classical Hodgkin's Lymphoma (NCT05683704) | Tianjin Medical University Cancer Institute and Hospital | 2022-09-01 |
| Dalpiciclib, Fulvestrant, Trastuzumab and Pertuzumab in HR Positive, HER2 Positive Metastatic Breast Cancer (NCT05574881) | Fudan University | 2022-09-01 |
| ZETAMET™ BONE GRAFT IN THE REPAIR OF BONE DEFECTS FROM METASTATIC BREAST CANCER IN VERTEBRAL BONES (NCT05280067) | Zetagen Therapeutics, Inc | 2022-09-01 |
| Diminishing Accelerated Long-term Forgetting in Mild Cognitive Impairment (NCT05289804) | University of Dublin, Trinity College | 2022-09-01 |
| ENACT: A Study of ENX-101 as Adjunctive Treatment in Patients With Focal Seizures (NCT05481905) | Engrail Therapeutics INC | 2022-09-01 |
| Sintilimab Combined With Regorafenib and HAIC in Patients With Colorectal Liver Metastasis (NCT05524155) | Tianjin Medical University Cancer Institute and Hospital | 2022-09-01 |
| Study of NUV-422 in Combination With Enzalutamide in Patients With mCRPC (NCT05191017) | Nuvation Bio Inc. | 2022-09-01 |
| LEAC-102 for Advanced Colorectal Cancer (NCT02826837) | Taiwan Leader Biotech Corp. | 2022-09-01 |
| Capecitabine Plus Toripalimab Maintenance Therapy in Metastatic Nasopharyngeal Carcinoma After First-line Treatment (NCT05484375) | Affiliated Cancer Hospital & Institute of Guangzhou Medical University | 2022-09-01 |
| Efficacy of Canrenone as add-on Treatment in Moderate to Severe ARDS in COVID-19 (NCT04977960) | Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico | 2022-09-01 |
| Bacteriophage Therapy in First Time Chronic Prosthetic Joint Infections (NCT05269121) | Adaptive Phage Therapeutics, Inc. | 2022-09-01 |
| Study of NUV-422 in Combination With Fulvestrant in Patients With HR+HER2- aBC (NCT05191004) | Nuvation Bio Inc. | 2022-09-01 |
| TRT for ES-SCLC After First Line Treatment With Immune Checkpoint Inhibitors (NCT05544149) | Zhejiang Cancer Hospital | 2022-09-01 |
| Organ Preservation Strategy of Total Neoadjuvant Chemoradiotherapy for Low Rectal Carcinoma (NCT05563922) | Shanghai Zhongshan Hospital | 2022-09-01 |
| Probenecid (PB) to Treat Hereditary Nephrogenic Diabetes Insipidus (NDI), ADPKD Treated With Tolvaptan, and Severely Polyuric Patients With Previous Lithium Administration (NCT05190744) | Mayo Clinic | 2022-09-01 |
| Stem Cells and Secretomes for Infertility Therapy in Polycystic Ovary Syndrome (PCOS) Patients With Insulin Resistance. (NCT05279768) | PT. Prodia Stem Cell Indonesia | 2022-09-01 |
| FMT to Convert Response to Immunotherapy (NCT05251389) | The Netherlands Cancer Institute | 2022-08-31 |
| Platelet Reactivity With Fentanyl, Morphine, or no Narcotic (NCT05367336) | Corewell Health South | 2022-08-31 |
| Abiraterone, Enzalutamide, or Apalutamide in Castrate-sensitive Prostate Cancer. (NCT05422911) | Sun Pharmaceutical Industries Limited | 2022-08-31 |
| Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer (NCT05386108) | Stemline Therapeutics, Inc. | 2022-08-31 |
| Oxulumis® Suprachoroidal Microcatherization of Triesence® in Diabetic Macular Edema (NCT05512962) | Oxular Limited | 2022-08-31 |
| Exploratory Clinical Study of Penpulimab Combined With SOX in the Perioperative Treatment of Gastric Cancer (NCT05519202) | The Central Hospital of Lishui City | 2022-08-31 |
| 18F-DCFPyL Imaging as a Method to Assess Treatment Response to Stereotactic Body Radiation Therapy (NCT05155046) | National Cancer Institute (NCI) | 2022-08-31 |
| Three Antidiarrheal Strategies in HER2+/HR+ Early Breast Cancer Patients Treated With Extended Adjuvant Neratinib (NCT05252988) | Spanish Breast Cancer Research Group | 2022-08-31 |
| Fruquintinib Sequential BEV+FOLFIRI vs. BEV+FOLFIRI Sequential Fruquintinib in Metastatic Colorectal Cancer (NCT05447715) | Weijian Guo | 2022-08-31 |
| Neoadjuvant Folfirinox Combined With Pembrolizumab Followed by Surgery for Patients With Resectable Pancreatic Cancer (NCT05132504) | Baylor College of Medicine | 2022-08-31 |
| Sub-study of Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combination With Nirogacestat, Pomalidomide, and Dexamethasone in Participants With RRMM (NCT07150104) | GlaxoSmithKline | 2022-08-31 |
| Study to Evaluate Safety and Dosimetry of Lutathera in Adolescent Patients With GEP-NETs and PPGLs (NCT04711135) | Advanced Accelerator Applications | 2022-08-31 |
| A Study to Determine if New Types of Malaria Vaccines Are Safe, Effective and Lead to Immunity in Kenyan Adults (NCT03947190) | University of Oxford | 2022-08-31 |
| 177Lu-DTPA-Omburtamab Radioimmunotherapy for Leptomeningeal Metastasis From Solid Tumors (Breast, NSCLC, Malignant Melanoma) (NCT04315246) | Y-mAbs Therapeutics | 2022-08-31 |
| Anastrazole, Fulvestrant & Abemaciclib for HR+HER2- Metastatic Breast Cancer (NCT05524584) | University of California, Irvine | 2022-08-31 |
| A Study of Peresolimab (LY3462817) in Participants With Moderately-to-Severely Active Rheumatoid Arthritis (NCT05516758) | Eli Lilly and Company | 2022-08-31 |
| Emicizumab in Patients With Acquired Hemophilia A (NCT05345197) | University of Washington | 2022-08-31 |
| Inhaled Nitric Oxide for Cardiac Arrest in Pediatrics and Adults (iNOCAPA) (NCT05868109) | The Hospital for Sick Children | 2022-08-31 |
| A Study to Evaluate the Efficacy and Safety of JPI-547 in Platinum-resistant, Advanced/Relapsed Ovarian Cancer Subjects Previously Treated With a PARP Inhibitor (NCT05475184) | Onconic Therapeutics Inc. | 2022-08-31 |
| A Study to Assess the Efficacy and Safety of Namilumab in Participants With Chronic Pulmonary Sarcoidosis (NCT05314517) | Kinevant Sciences GmbH | 2022-08-31 |
| A Study of MG-K10 in Subjects With Atopic Dermatitis (NCT05466877) | Shanghai Mabgeek Biotech.Co.Ltd | 2022-08-31 |
| Safety, Tolerability and PK of Subcutaneous D-4517.2 in Subjects With Wet AMD or DME (NCT05387837) | Ashvattha Therapeutics, Inc. | 2022-08-31 |
| Nivolumab-ipilimumab and Chemoradiation for Cervical Cancer (NCT05492123) | Hospital Israelita Albert Einstein | 2022-08-30 |
| BEACON: A Study Evaluating the Safety and Efficacy of BEAM-101 in Patients With Severe Sickle Cell Disease (NCT05456880) | Beam Therapeutics Inc. | 2022-08-30 |
| Highly Selective CDK7 Inhibitor Q901 in Selected Advanced Solid Tumors (NCT05394103) | Qurient Co., Ltd. | 2022-08-30 |
| A Study of CM310 in Subjects With Chronic Pruritus (NCT05452343) | Keymed Biosciences Co.Ltd | 2022-08-30 |
| Neuropsychological Care for Maintaining Quality of Life After Radiation Therapy in Patients With Brain Metastases (NCT05503251) | Ohio State University Comprehensive Cancer Center | 2022-08-30 |
| Study of INV-102 Ophthalmic Solution in Adults With Moderate Symptomatic Dry Eye Disease (NCT05586152) | Invirsa, Inc. | 2022-08-30 |
| External Beam Therapy With Theranostic Radioligand Therapy for Oligometastatic Prostate Cancer (ProstACT TARGET) (NCT05146973) | Telix Pharmaceuticals (Innovations) Pty Limited | 2022-08-30 |
| Induction Immunochemotherapy in Stage III-IVa Head and Neck Cancer (NCT05551767) | City Clinical Oncology Hospital No 1 | 2022-08-30 |
| Phase 2 Study of DKN-01 in Colorectal Cancer (NCT05480306) | Leap Therapeutics, Inc. | 2022-08-30 |
| Nirogacestat in Ovarian Granulosa Cell Tumors (NCT05348356) | Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany | 2022-08-30 |
| The Effect of Prucalopride on Gastric Emptying in Intensive Care Unit Patients (NCT05496179) | Ain Shams University | 2022-08-30 |
| First-in-Human (FIH) Trial of 1A46 in Subjects with Advanced CD20 And/or CD19 Positive B-cell Hematologic Malignancies (NCT05348889) | Chimagen Biosciences, Ltd | 2022-08-30 |
| Prophylactic Radiotherapy of MInimally Symptomatic Spinal Disease (NCT05534321) | Baptist Health South Florida | 2022-08-29 |
| A Phase 2 Study of ACR-368 in Endometrial Adenocarcinoma (NCT05548296) | Acrivon Therapeutics | 2022-08-29 |
| Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Glycopyrronium (Bromide) in Children (6 to Less Than 12 Years) With Asthma (NCT05222529) | Novartis Pharmaceuticals | 2022-08-29 |
| TT-816 As Monotherapy or in Combination with a PD-1 Inhibitor in Patients with Advanced Cancers (SEABEAM) (MK3475-E88) (NCT05525455) | Teon Therapeutics, Inc. | 2022-08-29 |
| iTBS-DCS in Fibromyalgia (NCT05395494) | University of Calgary | 2022-08-29 |
| Temelimab as a Disease Modifying Therapy in Patients With Neuropsychiatric Symptoms in Post-COVID 19 or PASC Syndrome (NCT05497089) | GeNeuro SA | 2022-08-29 |
| Testing Atezolizumab With Selinexor in People ≥ 12 Years Old With Alveolar Soft Part Sarcoma, AXIOM Trial (NCT05333458) | National Cancer Institute (NCI) | 2022-08-29 |
| Phase 2b Study of MBS2320 in Participants With Methotrexate-Refractory RA (NCT05460832) | Modern Biosciences Ltd | 2022-08-29 |
| An Extension Study to Evaluate the Long-Term Efficacy, Safety and Tolerability of Minzasolmin (UCB0599) in Study Participants With Parkinson's Disease (NCT05543252) | UCB Biopharma SRL | 2022-08-29 |
| Pembrolizumab as Neoadjuvant Therapy for Resectable Stage IA3 to IIA Non-Small Cell Lung Cancer (NSCLC) (NCT04638582) | McGill University Health Centre/Research Institute of the McGill University Health Centre | 2022-08-28 |
| Comparison of Hemodynamic Changes With Morphine Versus Esmolol During Induction of Anaesthesia (NCT06065956) | Pakistan Navy Station Shifa Hospital | 2022-08-28 |
| Efficacy and Safety of TQB2450 Injection Combined With Chemotherapy ± Anlotinib Hydrochloride Capsules for Advanced Endometrial Cancer or Sarcoma of Uterus. (NCT05481645) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2022-08-26 |
| Preoperative Use of Pantoprazole for Prevention of Post Operative Nausea and Vomiting in Gynecologic Surgery (NCT06488001) | United States Naval Medical Center, Portsmouth | 2022-08-26 |
| Study of Inupadenant (EOS100850) With Chemotherapy as Second Line Treatment for Nonsquamous Non-small Cell Lung Cancer (NCT05403385) | iTeos Therapeutics | 2022-08-26 |
| Ultrasonic Deep Brain Stimulation During Anesthetic Sedation (NCT05495945) | University of Michigan | 2022-08-26 |
| The Efficacy of a Subanesthetic Doses of IV Ketamine in the Treatment Drug Resistant Epilepsy (NCT05019885) | Madeline Fields | 2022-08-26 |
| Oncolytic Adenovirus Combined With PD-1 Inhibitor in Patients With Non-muscle-invasive Bladder Cancer (NCT05564897) | Zhejiang Cancer Hospital | 2022-08-26 |
| H002 in Patients With EGFR Mutation Locally Advanced or Metastatic NSCLC (NCT05552781) | RedCloud Bio | 2022-08-26 |
| Clinical Trial of YH32367 in Patients With HER2 Positive Locally Advanced or Metastatic Solid Tumor (NCT05523947) | Yuhan Corporation | 2022-08-26 |
| Evexomostat Plus PI3K or AKT Inhibitor and Fulvestrant in Patients With a PI3K Alteration and HR+/Her2- Breast Cancer (NCT05455619) | SynDevRx, Inc. | 2022-08-26 |
| A Study of LM-108 as Monotherapy or in Combination With Antitumor Therapies in Subjects With Advanced Solid Tumors (NCT05518045) | LaNova Medicines Limited | 2022-08-26 |
| Growth Hormone in a Patient With a Dominant-Negative GHR Mutation (NCT05382637) | Children's National Research Institute | 2022-08-26 |
| Chiauranib for Advanced Solid Malignant Tumors and Relapsed/Refractory SCLC. (NCT05271292) | Chipscreen Biosciences, Ltd. | 2022-08-26 |
| A Study of AK104 in Combination With Chiauranib in Patients With Extensive Stage Small Cell Lung Cancer (NCT05505825) | Akeso | 2022-08-26 |
| The Combination of Radiotherapy, Chemotherapy and Immunotherapy in High-Risk Localized Soft Tissue Sarcoma (NCT05774275) | Fudan University | 2022-08-25 |
| Efficacy and Safety of Fecal Microbiota Transfer (FMT) for Recurrent Urinary Tract Infections in Women (NCT07194941) | Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal | 2022-08-25 |
| Chiauranib for Advanced or Unresectable Soft Tissue Sarcoma(STS) (NCT05497843) | Chipscreen Biosciences, Ltd. | 2022-08-25 |